Sai Life Sciences Limited — Others, 18-08-2025: Shareholders meeting

Sai Life Sciences held its 26th Annual General Meeting virtually. The company recently completed a successful IPO, oversubscribed 10.27 times with bids for 39.85 Cr shares against 3.87 Cr on offer. Shares debuted at a premium, reflecting strong investor confidence. This IPO has strengthened the balance sheet by reducing debt. For FY2024-25, revenue grew 16% to ₹1,695 Cr, EBITDA rose 42% to ₹425 Cr, and net profit surged 105% to ₹170 Cr. The company actively expands its manufacturing capacity and R&D. The Board also approved re-appointments and remuneration adjustments for key directors, recognizing their contributions.